Hospitals are seeing more patients with tough autoimmune diseases get CAR T cell therapy. This treatment, once used only for blood cancers, is now an option for people who have run out of choices. But the rush to use it brings real risks. Thirty-one experts from major European and global groups have now stepped in. Their new update, published in The Lancet Rheumatology, aims to bring order to a fast-changing field. The stakes are high. For some, this therapy means a shot at remission. For others, a single mistake could be deadly.
The 2026 consensus recommendations come from the European Society for Blood and Marrow Transplantation, the International Society for Cell and Gene Therapy, and the Joint Accreditation Committee of ISCT and EBMT. Rheumatology and neurology leaders also contributed. This is a major rewrite of the 2024 guidance. The new document is not a strict rulebook. It is a shared plan. Most of the data still comes from small, single-arm studies. Large randomized trials are rare. The panel is blunt: doctors should not move faster than the evidence. But they also cannot wait for perfect studies while patients with severe, treatment-resistant disease have no other options.
As of the latest publications, there is no FDA-approved CAR T cell therapy specifically for autoimmune diseases; all candidates remain in clinical trials, even as some approach regulatory submission.
Who gets CAR T cell therapy and where
The new rules start with patient selection. Only people with severe autoimmune disease that stays active or gets worse despite standard treatments should be considered. The panel says doctors must give regular therapies a real chance first. If possible, patients should join clinical trials. This helps build better data and shows what works—and what does not. If a trial is not possible, the decision to use CAR T must be made by a team. Both autoimmune disease specialists and cell therapy experts must agree before moving forward. No shortcuts.
Where the treatment happens matters too. The panel says only centers accredited by FACT or JACIE for immune effector cell therapies should give CAR T for autoimmune disease. These centers follow strict rules for cell processing, manufacturing, and handling side effects. Not all diseases are the same. The panel rejects a one-size-fits-all approach. Refractory lupus nephritis, severe multiple sclerosis, and juvenile dermatomyositis each bring their own problems. Each needs a tailored plan.
Managing risk before and after infusion
The guidance spends a lot of time on what happens before and after the CAR T infusion. Every patient needs a full diagnostic workup, a treatment plan made just for them, and close immune monitoring. One big challenge stands out. Doctors must tell the difference between side effects from the therapy—like cytokine release syndrome or immune effector cell-associated neurotoxicity—and flares of the underlying autoimmune disease. Getting this wrong can be dangerous. Hematology, cell therapy, and autoimmune teams must work together. No exceptions.
Long-term follow-up is a must. Every patient who gets CAR T cell therapy should be entered into the EBMT Registry. This is how doctors will learn about long-term results, how long responses last, and what late side effects appear. The registry is growing to include autoimmune disease cases. This shift turns scattered stories into real evidence. The approach matches recent calls from the US Food and Drug Administration and the European Medicines Agency. Both agencies want longer tracking for patients who get genetically modified cells.
In August 2026, Novartis suspended eight clinical trials of its autologous CD19 CAR-T therapy, rap-cel, for autoimmune diseases after three fatal cases of a syndrome resembling immune effector cell-associated hemophagocytic lymphohistiocytosis (IEC-HS). The company announced an indefinite pause to investigate these events with stakeholders.
Pediatric patients and the future of CAR T in autoimmunity
Children and teens get special attention in the new rules. For some, a single CAR T infusion could mean freedom from years of steroids and immune-suppressing drugs. But the panel is clear. There is not enough data in young people. Extra care is needed. Teams must look at disease severity, past treatments, organ damage, fertility, and long-term quality of life before making a decision.
The panel also sets out what comes next. They want bigger, controlled trials—not just small, single-arm studies. They call for new biomarkers to predict who will respond and who might get sick from the therapy. They want new CAR targets for diseases that are not driven by B cells. And they want to make the therapy available outside a few top centers. The 2026 guidance is not final. It will change as new evidence comes in.
Cell therapy is moving fast. As reported earlier, CAR T cell therapies are being tested in more diseases. But the need for strict rules is the same everywhere.
The message from the panel is direct. CAR T cell therapy is no longer a fringe idea in autoimmunity. But its future depends on careful patient selection, teamwork, and constant data collection. Leaders in the field want to make sure that as CAR T moves from cancer wards to rheumatology clinics, it does so safely. This is the boldest effort yet to bring order to a fast-moving field. Hope must not outrun the facts.
A Deutsches Ärzteblatt research summary found that higher B-cell counts before infusion and strong systemic inflammation are linked to a higher risk of cytokine release syndrome (CRS) after CAR T cell therapy in autoimmune diseases.
